About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Sumitomo Pharma Co., Ltd.(4506) Summary

4506
TSE Prime
Sumitomo Pharma Co., Ltd.
520
JPY
-44
(-7.80%)
Apr 9, 3:30 pm JST
3.57
USD
Apr 9, 2:30 am EDT
Result
PTS
outside of trading hours
510
Apr 9, 9:54 pm JST
Summary Chart Historical News Financial Result
PER
12.9
PBR
1.24
Yield
ー%
Margin Trading Ratio
4.82
Stock Price
Apr 9, 2025
Opening Apr 9, 9:03 am
544 JPY 3.73 USD
Previous Close Apr 8
564 JPY 3.82 USD
High Apr 9, 9:03 am
544 JPY 3.73 USD
Low Apr 9, 1:29 pm
500 JPY 3.45 USD
Volume
5,173,900
Trading Value
2.67B JPY 0.02B USD
VWAP
515.91 JPY 3.55 USD
Minimum Trading Value
52,000 JPY 357 USD
Market Cap
0.21T JPY 1.43B USD
Number of Trades
3,946
Liquidity & Number of Trades
As of Apr 9, 2025
Liquidity
High
1-Year Average
2,207
1-Year High Feb 4, 2025
12,415
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 270,300 2,360,800 8.73
Mar 28, 2025 1,298,800 2,196,900 1.69
Mar 21, 2025 1,270,200 2,301,300 1.81
Mar 14, 2025 1,278,300 2,348,400 1.84
Mar 7, 2025 1,382,900 2,427,200 1.76
Company Profile
Sumitomo Pharma Co., Ltd. is a mid-sized pharmaceutical company originating from the Sumitomo Chemical group. The company focuses on developing drugs in the areas of psychiatry and neurology, oncology, and regenerative medicine.
Sector
Pharmaceuticals
Sumitomo Pharma's core business is the manufacturing, procurement, and sales of prescription pharmaceuticals, while also dealing with medical devices. The company prioritizes psychiatry, neurology, and oncology as its key therapeutic areas. In Japan, Sumitomo Pharma conducts manufacturing and sales of prescription pharmaceuticals through its subsidiaries. Additionally, through a joint venture with its parent company Sumitomo Chemical, it engages in contract development and manufacturing in the field of regenerative medicine and cell therapy. Sumitomo Pharma is also actively expanding globally, with operations in North America, China, Southeast Asia, and Taiwan. The company has established subsidiaries in various regions to conduct local pharmaceutical manufacturing, sales, and information provision activities.